Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 3

3(37.5%)

Phase 1

1(12.5%)

N/A

1(12.5%)

8Total

Phase 2(3)

Phase 3(3)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03598218Not ApplicableCompleted

Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma

Role: lead

NCT05527470Phase 3Recruiting

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: lead

NCT05097209Phase 2Recruiting

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Role: lead

NCT04350190Phase 2Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Role: lead

NCT03701451Phase 1Unknown

Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma

Role: lead

NCT03612219Phase 2Unknown

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Role: lead

NCT02434614Phase 3Unknown

Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: lead

NCT02057406Phase 3Completed

Omega 3 for Treatment of Depression in Patients With Heart Failure

Role: lead

All 8 trials loaded